Female Sexual Dysfunction Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Female Sexual Dysfunction Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Female Sexual Dysfunction Treatment Market

The female sexual dysfunction treatment market size was valued at USD 452.3 million in 2022, and the market is now projected to grow from USD 451.7 million in 2023 to USD 993.9 million by 2030, exhibiting a CAGR of 11.9% during the forecast period of 2023-2030.

The female sexual dysfunction treatment market growth faced a decrease in the year 2020 due to the COVID-19 outbreak which forced the patients from accessing treatments and affected drug supplies. However, in 2021 due to the high number of female patients, the demand for the treatment of sexual disease went up. The organization began adding telepharmacies and retail distribution to their service methods. Another strategy was the expanding geographical coverage and business licensing by the industry players, contributing to the rise in the international marketplace.

Female sexual dysfunction treatment is now more focused due to some side effects resulting from hormonal therapy. Market participants are also focusing on medical trials and discovering new medications for postmenopausal women with fewer side effects. Government policies, particularly increased manufacturing capabilities to address the remedy, are also advancing the female sexual dysfunction treatment market share. The marketplace is expected to grow very high in the forecast year due to the money invested in research and development.

Furthermore, the increased instances of female sexual dysfunction disorder have made more women opt for the remedy such as lotions and vaginal drugs. In the advanced region hormonal treatments which improve lubrication and sensation have also boosted the market. Also, the ease, affordability and availability of those therapies are coupled with the generalized usability of those therapies. The key industry players are obtaining regulatory approval to access new markets, consequently increasing the marketplace.

Comprehensive Analysis of Female Sexual Dysfunction Treatment Market

The female sexual disorder treatment market and healthcare industry is rising at an exponential charge due to its marketplace segmentation. This market enlargement efficaciously affords targeted local checks thinking about the dominant delivery and demand forces that affect the healthcare enterprise. These segmentations are methodically segregated by drug, by disease, by route of administration and by distribution channel. The drug includes, Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Others. The disease includes, Hypoactive Sexual Desire Disorder (HSDD), Dyspareunia and Others. The route of administration includes, Oral, Parenteral and Topical. The distribution channel includes, Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies.

North America is the largest marketplace, valued at USD 404.4 million in 2022. The most important boom has been due to the growing penetration of female sexual disorder remedy-related products among females. The North American market also expands due to licensing products between manufacturers and the approval of new therapies for diseases.

The market players play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, Sprout Pharmaceuticals, Inc. (U.S.), Mayne Pharma Group Limited (Australia), Duchesnay Pharmaceutical Group Inc. (Canada), PALATIN (U.S.), Freya Pharma Solutions B.V. (Netherlands), Acerus Pharmaceuticals Corporation (Canada), Millicent Pharma Ltd. (Endoceutics, Inc.) (Ireland) and Pfizer Inc. (U.S.). These market players provide a level-playing competitive landscape.

In January 2023, Mayne Pharma Group Limited completed the signing of a product licensing agreement with TherapeuticsMD, Inc. By this agreement, Mayne Pharma has the option to manage three patented innovative women’s health products comprising IMVEXXY.

Segmentation Table

Global Female Sexual Dysfunction Treatment Market Scope

Study Period 2017-2030

Base Year 2022

Forecast Period 2023-2030

Growth Rate CAGR of 11.9% from 2023 to 2030

Historical Period 2017-2021

Unit Value (USD Billion)

Segmentation By Drug, Disease, Route of Administration, Distribution Channel, and Region

By Drug Flibanserin

Bremelanotide

Ospemifene

Estrogen Therapy

Others

By Disease Hypoactive Sexual Desire Disorder (HSDD)

Dyspareunia

Others

By Route of Administration Oral

Parenteral

Topical

By Distribution Channel Hospital Pharmacies

Drug Stores & Retail Pharmacies

Online Pharmacies

By Region North America (By Drug, Disease, Route of Administration, Distribution Channel, and Country)

U.S.

Canada

Europe (By Drug, Disease, Route of Administration, Distribution Channel and, Country/ Sub Region)

Germany

U.K.

France

Italy

Spain

Rest of Europe

Asia Pacific (By Drug, Disease, Route of Administration, Distribution Channel, and Country/ Sub Region)

Japan

China

India

Australia

Southeast Asia

Rest of Asia Pacific

Rest of the World (By Drug, Disease, Route of Administration, and Distribution Channel)


Please Note: It will take 5-6 business days to complete the report upon order confirmation.